Last reviewed · How we verify
SC0062 medium dose
At a glance
| Generic name | SC0062 medium dose |
|---|---|
| Sponsor | Biocity Biopharmaceutics Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SC0062 medium dose CI brief — competitive landscape report
- SC0062 medium dose updates RSS · CI watch RSS
- Biocity Biopharmaceutics Co., Ltd. portfolio CI